Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2026 10:56 ET | Source: Research and Markets

Glypican-3 (GPC3) Targeted Therapy Market Competitor Analysis Report 2026: More Than 20 Product Candidates are in Clinical Development and Further Eight at IND or IND-enabling Stage

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
February 20, 2026 10:55 ET | Source: Research and Markets

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2026: PYLARIFY Exceeds US$ 1 Billion in Net Sales and Became the First Ever Blockbuster Radiodiagnostic

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics" report has been added to ResearchAndMarkets.com's offering.This competitive...
February 19, 2026 09:39 ET | Source: Research and Markets

Cancer & Antibody Conjugates Patent Landscape Analysis 2025: 3761 Patent Families - IP Trends, Including Time Evolution of Published Patents and Countries of Patent Filings

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cancer & Antibody Conjugates Patent Landscape Analysis 2025" report has been added to ResearchAndMarkets.com's offering.Key Features: PDF >...
February 19, 2026 07:33 ET | Source: Research and Markets

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapeutics in Cancer Treatment: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for radioligand...
February 11, 2026 08:05 ET | Source: VivoSim Labs, Inc.

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
February 03, 2026 07:53 ET | Source: Research and Markets

Antibody Drug Conjugates (ADC) Market Forecasts 2026-2030 with Executive and Consultant Guides - Fast-Tracking, Funding Availability, and Targeted Solutions Spurs Expansion

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Forecasts (2026-2030) by Cancer, Payload, Target, Product, User and Country/Region with Executive and Consultant...
January 29, 2026 08:00 ET | Source: Breakthru Medicine

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

Breakthru Medicine emerges from stealth with $60M Series A in cancer drug development
January 19, 2026 04:07 ET | Source: Research and Markets

Global Antibody Drug Conjugates Market to Surge from USD 12.26 Billion in 2024 to USD 32.11 Billion by 2033

Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Urothelial Carcinoma, Ovarian Cancer, Breast...
January 06, 2026 08:00 ET | Source: Biolojic Design

Biolojic Design Appoints Roger Waltzman as Chief Medical Officer

Biolojic Design Appoints Roger Waltzman as new Chief Medical Officer
November 27, 2025 09:00 ET | Source: Research and Markets

B7-H3-Targeted Immunotherapy Competitor Analysis Report 2025: More Than 15 Product Candidates are in Clinical Development, with Several Already in Clinical Phase III

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "B7-H3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...